TrialCurveSCOT (primary analysis): reconstructed Kaplan–Meier curves
3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial. Curves rebuilt as patient-level data (Guyot 2012) and checked against the statistics printed on the figure.
| Publication | Lancet Oncol. 2018 Apr;19(4):562–78. doi: 10.1016/S1470-2045(18)30093-7 |
|---|---|
| DOI | 10.1016/S1470-2045(18)30093-7 |
| Registry | — |
| Phase | — |
| Conditions | — |
| Interventions | — |
| Sponsor | — |
| Enrolment | — |
| Source licence | Figure published under CC BY 4.0 |
Disease-free survival
From figure panel A · validated against the values printed on the figure · curve source: vision model
Reconstructed from the published curve. Median: 3 months not reached; 6 months not reached. Survival at 2 years: 3 months 81%; 6 months 81%. Hazard ratio 3 months vs 6 months 1.00 (95% CI 0.90–1.10).
| Arm | N | Events | Median (Years) |
|---|---|---|---|
| 3 months | 3035 | 736 | not reached |
| 6 months | 3030 | 744 | not reached |
- 3 months vs 6 months: reconstructed HR 1.00 (95% CI 0.90–1.10)
Landmark survival (reconstructed)
| Time | 3 months | 6 months |
|---|---|---|
| 1 yr | 89.2% | 91.0% |
| 2 yr | 81.2% | 81.2% |
| 3 yr | 77.0% | 77.0% |
| 5 yr | 71.8% | 70.7% |
| 7 yr | 67.1% | 67.6% |
Checks against the published figure
- 3 months events: printed 740, reconstructed 736 pass
- 3 months n: printed 3035, reconstructed 3035 pass
- 6 months events: printed 742, reconstructed 744 pass
- 6 months n: printed 3030, reconstructed 3030 pass
- hazard ratio: printed 1.01, reconstructed 0.997 pass
Overall survival
From figure panel B · validated against the values printed on the figure · curve source: vision model
Reconstructed from the published curve. Median: 3 months not reached; 6 months not reached. Survival at 2 years: 3 months 94%; 6 months 94%. Hazard ratio 6 months vs 3 months 1.00 (95% CI 0.87–1.15).
| Arm | N | Events | Median (Years) |
|---|---|---|---|
| 3 months | 3035 | 392 | not reached |
| 6 months | 3030 | 394 | not reached |
- 6 months vs 3 months: reconstructed HR 1.00 (95% CI 0.87–1.15)
Landmark survival (reconstructed)
| Time | 3 months | 6 months |
|---|---|---|
| 1 yr | 97.4% | 97.4% |
| 2 yr | 94.2% | 94.2% |
| 3 yr | 90.3% | 90.3% |
| 5 yr | 81.7% | 82.0% |
| 7 yr | 76.1% | 77.8% |
Checks against the published figure
- 3 months events: printed 393, reconstructed 392 pass
- 3 months n: printed 3035, reconstructed 3035 pass
- 6 months events: printed 394, reconstructed 394 pass
- 6 months n: printed 3030, reconstructed 3030 pass
- hazard ratio: printed 0.994, reconstructed 1 pass
Disease-free survival — CAPOX
From figure panel A · validated against the values printed on the figure · curve source: vision model
Reconstructed from the published curve. Median: 3 months not reached; 6 months not reached. Survival at 2 years: 3 months 81%; 6 months 80%. Hazard ratio 3 months vs 6 months 0.93 (95% CI 0.82–1.05).
| Arm | N | Events | Median (Years) |
|---|---|---|---|
| 3 months | 2049 | 499 | not reached |
| 6 months | 2043 | 539 | not reached |
- 3 months vs 6 months: reconstructed HR 0.93 (95% CI 0.82–1.05)
Landmark survival (reconstructed)
| Time | 3 months | 6 months |
|---|---|---|
| 1 yr | 87.4% | 88.4% |
| 2 yr | 80.8% | 79.7% |
| 3 yr | 76.6% | 76.1% |
| 5 yr | 72.2% | 69.3% |
| 7 yr | 69.2% | 65.6% |
Checks against the published figure
- 3 months events: printed 492, reconstructed 499 pass
- 3 months n: printed 2049, reconstructed 2049 pass
- 6 months events: printed 529, reconstructed 539 pass
- 6 months n: printed 2043, reconstructed 2043 pass
- hazard ratio: printed 0.944, reconstructed 0.928 pass
Disease-free survival — FOLFOX
From figure panel B · validated against the values printed on the figure · curve source: vision model
Reconstructed from the published curve. Median: 3 months not reached; 6 months not reached. Survival at 2 years: 3 months 81%; 6 months 83%. Hazard ratio 6 months vs 3 months 0.84 (95% CI 0.70–1.01).
| Arm | N | Events | Median (Years) |
|---|---|---|---|
| 3 months | 986 | 245 | not reached |
| 6 months | 987 | 212 | not reached |
- 6 months vs 3 months: reconstructed HR 0.84 (95% CI 0.70–1.01)
Landmark survival (reconstructed)
| Time | 3 months | 6 months |
|---|---|---|
| 1 yr | 89.5% | 91.0% |
| 2 yr | 81.0% | 83.2% |
| 3 yr | 76.2% | 79.3% |
| 5 yr | 71.1% | 73.6% |
| 7 yr | 62.8% | 73.6% |
Checks against the published figure
- 3 months events: printed 248, reconstructed 245 pass
- 3 months n: printed 986, reconstructed 986 pass
- 6 months events: printed 213, reconstructed 212 pass
- 6 months n: printed 987, reconstructed 987 pass
- hazard ratio: printed 1.16, reconstructed 1.19 pass
Disease-free survival — T1-3/N1
From figure panel A · validated against the values printed on the figure · curve source: vision model
Reconstructed from the published curve. Median: 3 months not reached; 6 months not reached. Survival at 2 years: 3 months 89%; 6 months 87%. Hazard ratio 3 months vs 6 months 0.90 (95% CI 0.75–1.09).
| Arm | N | Events | Median (Years) |
|---|---|---|---|
| 3 months | 1331 | 201 | not reached |
| 6 months | 1332 | 221 | not reached |
- 3 months vs 6 months: reconstructed HR 0.90 (95% CI 0.75–1.09)
Landmark survival (reconstructed)
| Time | 3 months | 6 months |
|---|---|---|
| 1 yr | 93.3% | 93.5% |
| 2 yr | 88.9% | 87.2% |
| 3 yr | 85.1% | 84.1% |
| 5 yr | 82.3% | 79.1% |
| 7 yr | 68.4% | 79.1% |
Checks against the published figure
- 3 months events: printed 202, reconstructed 201 pass
- 3 months n: printed 1331, reconstructed 1331 pass
- 6 months events: printed 223, reconstructed 221 pass
- 6 months n: printed 1332, reconstructed 1332 pass
- hazard ratio: printed 0.908, reconstructed 0.905 pass
Disease-free survival — T4 or N2
From figure panel B · validated against the values printed on the figure · curve source: vision model
Reconstructed from the published curve. Median: 3 months 6.0 years; 6 months not reached. Survival at 2 years: 3 months 69%; 6 months 70%. Hazard ratio 6 months vs 3 months 0.93 (95% CI 0.82–1.07).
| Arm | N | Events | Median (Years) |
|---|---|---|---|
| 3 months | 1143 | 443 | 6.0 |
| 6 months | 1140 | 426 | not reached |
- 6 months vs 3 months: reconstructed HR 0.93 (95% CI 0.82–1.07)
Landmark survival (reconstructed)
| Time | 3 months | 6 months |
|---|---|---|
| 1 yr | 81.7% | 83.8% |
| 2 yr | 69.2% | 70.2% |
| 3 yr | 62.5% | 63.8% |
| 5 yr | 55.3% | 56.4% |
| 7 yr | — | 54.7% |
Checks against the published figure
- 3 months events: printed 439, reconstructed 443 pass
- 3 months n: printed 1143, reconstructed 1143 pass
- 6 months events: printed 417, reconstructed 426 pass
- 6 months n: printed 1140, reconstructed 1140 pass
- hazard ratio: printed 1.07, reconstructed 1.07 pass
About these data
Pseudo-IPD reproduces the published curves and numbers at risk; the rows are not real patients. Cite the publication (DOI above) and TrialCurve. The source figure is © the authors (CC BY 4.0); the charts here are redrawn from the reconstruction.
Load these data in R or Python
# R
library(survival)
d <- read.csv("https://trialcurve.com/data/trials/scot-primary-analysis-1.csv")
survfit(Surv(time, event) ~ arm, data = d)
coxph(Surv(time, event) ~ arm, data = d)
# Python
import pandas as pd
from lifelines import KaplanMeierFitter
d = pd.read_csv("https://trialcurve.com/data/trials/scot-primary-analysis-1.csv")
for arm, g in d.groupby("arm"):
KaplanMeierFitter().fit(g.time, g.event, label=arm).plot_survival_function()
Suggested citation: Lancet Oncol. 2018 Apr;19(4):562–78. doi: 10.1016/S1470-2045(18)30093-7 doi:10.1016/S1470-2045(18)30093-7. Reconstructed data: TrialCurve (2026), https://trialcurve.com/trials/scot-primary-analysis
Report a problem with these data
Related trials
- SCOT: Disease-free survival; Overall survival; Survival after recurrence (SAR)
- BREAKWATER: Overall survival
- Sequential vs upfront oxaliplatin in metastatic colorectal cancer: Overall survival
- HIPECT4 (final analysis): Disease-free survival; Locoregional control; Overall survival
- Cetuximab β + FOLFIRI in RAS/BRAF wild-type colorectal cancer: Overall survival; Progression-free survival (BIRC-assessed)
- FOCUS4-D: Progression-free survival
Need reconstructed data for other trials? Upload any Kaplan–Meier figure, or ask about the TrialCurve oncology library.
Reconstruct a figure Browse all trials